The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease
Open accessAbstract
Circulating microRNAs (miRNAs) are emerging as useful non‐invasive markers of disease. The objective of this study was to use a mouse model of prostate cancer as a tool to discover serum miRNAs that could be assessed in a clinical setting. Global miRNA profiling identified 46 miRNAs at significantly altered levels (p ≤ 0.05) in the serum of TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice with advanced prostate cancer compared to healthy controls. A subset of these miRNAs with known human homologues were validated in an independent cohort of mice and then measured in serum from men with metastatic castration‐resistant prostate cancer (mCRPC; n = 25) or healthy men (n = 25). Four miRNAs altered in mice, mmu‐miR‐141, mmu‐miR‐298, mmu‐miR‐346 and mmu‐miR‐375, were also found to be at differential levels in the serum of men with mCRPC. Three of these (hsa‐miR‐141, hsa‐miR‐298 and hsa‐miR‐375) were upregulated in prostate tumors compared with normal prostate tissue, suggesting that they are released into the blood as disease progresses. Moreover, the intra‐tumoral expression of hsa‐miR‐141 and hsa‐miR‐375 were predictors of biochemical relapse after surgery. This study is the first to demonstrate that specific serum miRNAs are common between human prostate cancer and a mouse model of the disease, highlighting the potential of such models for the discovery of novel biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
A pancreatic islet-specific microRNA regulates insulin secretion
Poy, M. N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., MacDonald, P. E., Pfeffer, S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004) · Nature · doi:10.1038/nature03076 · Cited by 2,102
Cited by
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., Wang, D., See, W., Costello, B. A., Quevedo, F., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.035 · Cited by 681
Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)
ALLEGRA, A., ALONCI, A., CAMPO, S., PENNA, G., PETRUNGARO, A., GERACE, D., & MUSOLINO, C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1647 · Cited by 359
U6 is not a suitable endogenous control for the quantification of circulating microRNAs
Xiang, M., Zeng, Y., Yang, R., Xu, H., Chen, Z., Zhong, J., Xie, H., Xu, Y., & Zeng, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.064 · Cited by 259
Profiling of circulating microRNAs for prostate cancer biomarker discovery
Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Høyer, S., Orntoft, T. F., & Sorensen, K. D. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0169-4 · Cited by 83
Circulating microRNAs as Promising Tumor Biomarkers
(2014) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2014.09.007 · Cited by 40
Metadata
- Authors
- Selth, L. A., Townley, S., Gillis, J. L., Ochnik, A. M., Murti, K., Macfarlane, R. J., Chi, K. N., Marshall, V. R., Tilley, W. D., & Butler, L. M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-11-03
- Volume
- 131
- Issue
- 3
- Pages
- 652-661
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2069660208
- Cited by
- 184
- References
- 3
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.